Printer Friendly

ALKERMES REPORTS THIRD QUARTER FINANCIAL RESULTS

 ALKERMES REPORTS THIRD QUARTER FINANCIAL RESULTS
 CAMBRIDGE, Mass., Feb. 13 /PRNewswire/ -- Alkermes, Inc.


(NASDAQ: ALKS) today reported total revenues for the three and nine months ended Dec. 31, 1991 of $726,837 and $1,023,039, respectively, compared with $72,859 and $869,848 for the comparable periods in 1990. The increase in revenues for the comparable three and nine month periods is due to an increase in interest income resulting from increased cash and short-term investments resulting from the completion of two public offerings of the company's common stock. This increase in revenues was offset in part by loss of contract revenues which resulted from the termination of a research and development agreement with Alkermes Investment Partners, L.P. in September 1990.
 The net loss for the three and nine months ended Dec. 31, 1991 was $1,386,551 (15 cents per share) and $4,878,877 (72 cents per share), respectively, compared with a net loss of $988,039 (17 cents per share) and $4,505,308 (80 cents per share), respectively, for the same periods in 1990. The net loss for the nine month period ended Dec. 31, 1990 included a one-time, non-cash charge of $2,211,361 for acquired research and development.
 The company's research and development expenditures, including those for preclinical development, continue to increase as the company expands its research and development activities as well as its staff.
 Alkermes, Inc. is a neuropharmaceutical company founded in 1987 that is focused on the development and commercialization of therapeutic and diagnostic products for the treatment of disorders of the central nervous system.
 -0- 2/13/92
 /CONTACT: Michael J. Landine of Alkermes, Inc, 617-494-0171, or Thomas A. Pearson of Pearson Communications, 215-648-3975 for Alkermes, Inc./
 (ALKS) CO: Alkermes Inc. ST: Massachusetts IN: MTC SU: ERN


TM-DH -- NE012 -- 9985 02/13/92 17:24 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 13, 1992
Words:308
Previous Article:VAALCO ENERGY INC. WEST LINAPACAN A-1 WELL UPDATE
Next Article:RS FINANCIAL CORP. ANNOUNCES EARNINGS FOR FOURTH QUARTER AND YEAR
Topics:


Related Articles
ALKERMES REPORTS SECOND QUARTER FINANCIAL RESULTS; PUBLIC OFFERING BOOSTS CASH POSITION
ALKERMES REPORTS YEAR-END FINANCIAL RESULTS
CORTEX 1992 REPORTS FOURTH QUARTER AND FULL YEAR RESULTS
CORTEX 1992 REPORTS FOURTH QUARTER AND FULL YEAR RESULTS
CORTEX 1992 REPORTS FOURTH QUARTER AND FULL YEAR RESULTS
Amylin Pharmaceuticals and Alkermes Sign Agreement For Development Of Long-Acting Formulation of AC2993 (Synthetic Exendin-4).
Amylin Pharmaceuticals Announces Successful Completion of AC2993 LAR Feasibility Work with Alkermes and Plans for Human Studies in 2001.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters